| Popis: |
Marium Husain,1 Amber D Hartman,2 Payal Desai3 1Division of Medical Oncology, 2Division of Palliative Medicine, 3Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA Abstract: Sickle cell disease (SCD) is a monogenetic disease but has a wide range of phenotypic expressions. Some of these differences in phenotype can be explained by genetic polymorphisms in the human globin gene. These polymorphisms can result in different responses to typical treatment, sometimes leading to inadequate therapeutics. Research is revealing more polymorphisms, and therefore, new targets for intervention to improve outcomes in SCD. This area of pharmacogenomics is continuing to develop. We provide a brief review of the current literature on pharmacogenomics in SCD and possible targets for intervention. Keywords: sickle cell disease, pharmacogenomics, hydroxyurea, opioids, HbF inducers, gene therapy |
